Mergers & Acquisitions Mergers & Acquisitions

ChrysCapital removes director from competing Indian firm to expand stake in Intas Pharmaceuticals

By Freny Patel
  • 21 Dec 2020 07:11
  • 21 Dec 2020 07:11
Private equity investor ChrysCapital was forced to remove its director from the board of Mankind Pharma and will not be able to exercise its veto rights in the company as a condition of securing merger clearance from the Indian competition authority to increase its minority stake in Intas Pharmaceuticals.

To view the latest version of this document and thousands of others like it, sign-in to MLex or register for a free trial.

Freny Patel


Freny has been covering antitrust law, M&A and regulations for over a decade, serving as Asia editor at Policy and Regulatory Report. Prior to joining as an editor at Mergermarket, she headed the banking bureau of a leading Indian financial daily, Business Standard. When India privatized the insurance sector, she had her own column in The Observer.

Discover MLex

Stay on top of global regulatory developments

Latest News